Grace Therapeutics, Inc. Financial Ratios
GRCE|FY2023 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2023 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.68 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2023)
Return on Equity
-9.1%
Profit Margin
-9.8%
Net Income / Revenue
Asset Turnover
1.26
Revenue / Total Assets
Equity Multiplier
0.73
Total Assets / Equity
Composite: -9.1% (reported: -9.1%)
Profitability
Liquidity
Current Ratio
8.59
Quick Ratio
8.59
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
1.26
Inventory Turnover
-
Days Sales Outstanding
3 days
As of FY2023 · SEC 10-K · Updated Jun 24, 2026
Earnings Quality
Accrual Ratio
+9.4%
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.